Skip to main content .


BARDA and Genentech expand partnership to begin Phase 2 clinical trial to evaluate investigational treatments for COVID-19 patients

BARDA Response

BARDA and Genentech, part of the Roche Group and headquartered in South San Francisco, are partnering to support the acceleration of a Phase 2 clinical trial to evaluate two novel therapeutics for the potential treatment of hospitalized patients with severe COVID-19 pneumonia.

The single, randomized, placebo controlled Phase 2 clinical trial will evaluate the safety and efficacy of the two investigational drugs, MSTT1041A (anti-ST2) and UTTR1147A (IL-22-Fc) in approximately 300 patients with severe COVID-19 pneumonia requiring supplemental oxygen. Both may prevent COVID-19 pneumonia progression to Acute Respiratory Distress Syndrome (ARDS) and/or promote convalescence of patients with ARDS. ST2 is the receptor for IL-33, and inhibition of IL-33 signaling via inhibition of ST2 is predicted to reduce maladaptive hyperinflammatory responses. IL22 is a cytokine that promotes epithelial and endothelial cell repair and may prevent secondary bacterial infections.

Currently there are no approved treatments for ARDS caused by COVID-19 pneumonia. This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

About Genentech:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. Genentech, a member of the Roche Group, has headquarters in South San Francisco, California. 

Last Updated: June 01, 2020

Website Refresh

www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov